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ABSTRACT
Objective: To estimate the cost-effectiveness of repeated
screening for chlamydia trachomatis at various time
intervals compared to one-off screening of Dutch young
adults.
Methods: We used a dynamic model to fully take the spread
of the disease over time in the population into account, with
data being used gathered within the context of a recently
performed pilot study in The Netherlands. The screening
frequencies analyzed were: every year, every 2 years, every
5 years, and every 10 years. The strategies were compared in
terms of incremental cost-effectiveness, expressed as the net
costs per quality-adjusted life-year (QALY).
Results: For all interval strategies, with the exception of
screening every year, incremental cost-effectiveness stays
below the informal Dutch threshold of €20,000 per QALY.
Conclusion: From a health-economic point of view, for the
Dutch situation, we estimated screening every 2 years as the
optimal strategy among the options investigated.
Keywords: chlamydia trachomatis, cost-utility analysis,
dynamic model, screening.
Previously we estimated the cost-effectiveness of a
systematic chlamydia trachomatis (CT) screening
program for a young Dutch adult, which recently has
been published in this Value in Health [1]. This analy-
sis concerned an initial one-off screening, without any
subsequent repeated screenings assumed. We used a
dynamic model to fully take the spread of the disease
over time in the population into account, with data
being used that were gathered within the context of a
recently performed pilot study in The Netherlands [2].
We showed that, in baseline analysis, the prevention
of one major outcome as a result of the screening
program costs €373 for the Dutch situation. Here,
symptomatic pelvic inﬂammatory disease, chronic
pelvic pain, ectopic pregnancy, infertility, and neonatal
pneumonia were considered major outcomes and were
aggregated into one ﬁgure.
The frequency of subsequent screening is a logical
topic of discussion before implementation of such a
program. Hence, in this article we present additional
research on the cost-effectiveness of repeated system-
atic screening at various time intervals compared to the
one-off screening presented before. Furthermore, as
among many other countries, in The Netherlands
interventions are valued with respect to the cost per
quality-adjusted life-year (QALY), we linked quality
weights to the complications related to CT-infections
to enable such estimates of the costs per QALY. In
The Netherlands, interventions are considered cost-
effective if cost-effectiveness is estimated below a
threshold of €20,000 per QALY [3]. This threshold is
informal and certainly not undisputed, but often used
by decision-makers.
Methods
Model
We used a deterministic SIS (Susceptible-Infected-
Susceptible) model to estimate the impact of the
screening program on the incidence and prevalence of
CT in the population [4]. We followed a heterosexual
population of 100,000 men and women with a sex
ratio 1:1 and a uniform age distribution over
15–29 years. The population was divided according to
sex, sexual activity, and condition (susceptible, symp-
tomatically infected, or asymptomatically infected).
We used the output of the dynamic model as input for
a progression-of-disease tree to calculate the number
of complications and associated costs related to a
speciﬁc incidence. The dynamic model, progression-
of-disease tree, and the parameter values used are
described in detail in the research previously published
[1]. In this analysis, we made the same assumptions as
we did in the baseline analysis of that research. Nev-
ertheless, instead of a time horizon of 10 years, a time
horizon of 20 years was used to fully acknowledge
the dynamics of repeated screening at different time
intervals.
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Screening Strategies
The systematic screening program targeted 15- to
29-year-old men and women and included (partner)
treatment [1,2]. We compared the one-off screening
with repeated screening on various time intervals. The
screening frequencies analyzed were: every year, every
2 years, every 5 years, and every 10 years. We modeled
the screening from t = 0 to t = 10 years (e.g., screening
every 5 years was modeled on t = 0, t = 5, and
t = 10 years). The period of t = 10 years to t = 20 years
was included to fully grasp the long-term effects and
ﬁnancial beneﬁts of the screening programs, inclusive
the full effects of any screening at t = 10 years. As in
the previous article, we assumed that the infection
reached endemic equilibrium before the implementa-
tion of the screening program. Furthermore, we
assumed that the participation rate was constant over
time (47% of the women and 33% of the men [1,2]).
Cost-Effectiveness Analysis
We expressed cost-effectiveness as the net costs per
QALY. We linked quality weights to the health states
related to the complications of both symptomatic
and asymptomatic CT-infections. The quality weights
together with their durations were based on the Health
Utility Index and were obtained from a study commis-
sioned by the Institute of Medicine [5]. The perspective
of the analysis was that of the society: both direct
medical costs and indirect costs of production losses
were included. The cost estimates are fully described in
the previous research [1]. Future costs and future com-
plications were discounted at a rate of 4% per year
according to Dutch guidelines for pharmacoeconomic
research [6].
Results
The estimated costs and QALYs for the different
screening strategies are presented in Table 1 and
Figure 1. Within a time frame of 20 years, the cost of
the one-off screening program (€1,212,778) is totally
offset by the averted cost of €1,434,056. Repeated
screening on various time intervals leads to both an
increase in QALYs gained and total net costs. Obvi-
ously, the higher the frequency the more QALYs are
gained. Nevertheless, this increase in QALYs is accom-
panied by an increase in the net costs per QALY. The
appropriate comparison between mutually exclusive
programmes, in that if one strategy is implemented the
others will not, is in terms of the incremental cost-
effectiveness [7]. Therefore, in Table 1 the incremental
costs-effectiveness ratios (ICERs) are calculated for
each successive alternative, from the least costly to the
most. In Figure 1, the ICERs are given by the slope of
the line joining any two points (alternatives). Here, a
10-year screening strategy is eliminated because of
extended dominance, as its ICER is higher than that of
the next more effective treatment (screening every
5 years). After exclusion of the dominated strategy,
the recalculated ICER for a 5-year screening strategy
is €1793 per QALY. For all interval strategies, with
the exception of screening every year, incremental
Table 1 Outcomes of the different screening programs for a
population of 100,000 persons (costs in 2002 euros)
Strategy Costs QALYs ICER*
One-off -221,278 362 -611
Every 10 years 33,131 501 Dominated†
Every 5 years 327,625 668 1,793
Every 2 years 2,099,562 939 6,539
Every 1 year 6,316,683 1,065 33,469
*ICER is calculated for each successive alternative, from the least costly to the most.
†A strategy is dominated as its ICER is higher than the next more effective treatment.
ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-year.
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Figure 1 Total costs and effectiveness of the different chlamydia tra-
chomatis screening strategies, where A = one-off, B = every 5 years,
C = every 2 years, and D = every year.The incremental cost-effectiveness
ratios are given by the slope of the line joining any two points. QALY,
quality-adjusted life-year.
Figure 2 Chlamydia trachomatis prevalence in the whole population as a
result of screening every 2 years (t = 0, t = 2, t = 4, t = 6, t = 8, and t = 10).
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cost-effectiveness stays below the informal Dutch
threshold of €20,000 per QALY. For illustrative pur-
poses, the reduction in CT-prevalence as a result of
screening every 2 years is depicted in Figure 2. The
overall prevalence drops from 1.79% at steady state to
a minimum of 0.09% after the last screening (t = 10),
after which the prevalence slowly increases again as a
result of the (somewhat restricted) mixing within and
between the different sexual activity groups.
Discussion
Application of our dynamic model shows that the one-
off systematic screening program is estimated cost-
saving within a time horizon of 20 years. It is obvious
that shortening the time horizon is accompanied by a
decrease in averted complications and associated costs.
For example, as in our previous research, within a time
horizon of 10 years the program costs are not fully
off-set by the averted costs (one has to pay €373 per
major outcome averted) [1]. Ideally, the time horizon
should be a population’s entire lifetime, but as various
inﬂuencing factors may change during that period and
could lead to invalid results, one should choose a rea-
sonable time horizon to produce plausible results. As
in the previous research, we opted for a period of
10 years after the last screening in any of the strategies
investigated, which was at t = 0 for the previous article
and t = 10 in the current one. The latter implies a full
period of analysis with a time horizon of 20 years to
take the effects of repeated screening strategies into
account.
Even though repeated screening leads to an increase
in QALYs gained, society has net to pay for the pre-
vention of CT-complications. The inﬂuence of the
prevalence on the cost-effectiveness of a CT-screening
program is clearly shown in Table 1; as the frequency
of screening is decreased, the prevalence is able to
return to a higher level before the next screening starts
and so relatively more complications (and associated
costs) can be averted per screening. For example, of all
strategies screening every year will avert most compli-
cations, but the price one has to pay per QALY is
highest as well. So, among other things it depends on
the decision-maker’s willingness to pay which program
should be implemented. We assume the participation
rate remains the same every year. Nevertheless, it could
be possible that this rate drops as the frequency
increases.
In conclusion, from a health-economic point of
view, the objective is to choose the strategy that gains
the maximum number of QALYs with the cost-
effectiveness threshold as constraint. So, irrespective of
other concerns (e.g., feasibility) of the examined strat-
egies, we estimated screening every 2 years as the best
option for the Dutch situation given the informal
threshold of €20,000 per QALY. We note that
other—not yet investigated—strategies, such as men
and women tested negative are screened every 2 years
and those tested positive are screened every 6 months,
could be cost-effective alternatives as well. Further
research on the cost-effectiveness of such alternative
strategies is required.
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